CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response

AIDS

Volumn 15, Issue 17, 2001, Pages 2259-2266

  Brumme, Zabrina L ^a   Chan, Keith J ^a   Dong, Winnie ^a   Hogg, Robert ^a   O'Shaughnessy, Michael V ^a   Montaner, Julio S G ^a   Harrigan, P Richard ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

32; Antiretroviral therapy; CCR5 promoter; Polymorphism

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CORRELATION ANALYSIS; DNA SEQUENCE; FOLLOW UP; GEL ELECTROPHORESIS; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; ALLELE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLASSIFICATION; COHORT ANALYSIS; CYTOLOGY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; GENE FREQUENCY; GENOTYPE; HIV INFECTIONS; HUMANS; LINKAGE DISEQUILIBRIUM; PATIENT COMPLIANCE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, CCR5; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035940691     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200111230-00007     Document Type: Article

References (23)

1. Molecular cloning and functional expression of a new human CC-chemokine receptor gene
2. Identification of a major coreceptor for primary isolates of HIV-1
3. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
4. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
5. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiple-exposed individuals to HIV-1 infection
6. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
7. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene
8. Increased frequency of CCR-5 32 heterozygotes among long-term non-progressors with HIV-1 infection
9. Genetic acceleration of AIDS progression by a promoter variant of CCR5
10. CCR5 promoter polymorphism and HIV-1 disease progression
11. CCR5 promoter polymorphisms, CCR5 59020 and ccr5 59353C, are under represented in HIV-1-infected long-term non-progressors
12. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32
13. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a ccr5 promoter mutation
14. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
15. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression
16. A 32 bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness
17. Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression
18. Treatment history and baseline viral load, but not viral tropism or CCR5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment
19. CCR5 delta32 deletion and response to HAART in HIV-1-infected patients
20. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
21. CCR5Delta32 gene deletion in HIV-1 infected patients
22. No evidence for an effect of the CCR5D32/+ and CCR2b 641/+ mutations on human immunodefiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users
23. Association of the CCR532 mutation with improved response to antiretroviral therapy